Contreras

Case MDL No. 2924 Document 1439 Filed 04/11/ Page1of3

DISTREN cone □□ □□□ true = ‘ UNITED STATES JUDICIAL PANEL ls} ‘ us □□□ Gut on 2 SA, Lf [sg _ J. Adams _ MULTIDISTRICT LITIGATION Clas von_Apr 12, 3024"

IN RE: ZANTAC (RANITIDINE)

PRODUCTS LIABILITY LITIGATION MDL No. 2924

TRANSFER ORDER

Before the Panel:* Plaintiff in the Contreras action listed on Schedule A moves under Panel Rule 7.1 to vacate our order that conditionally transferred Contreras to the Southern District of Florida for inclusion in MDL No. 2924. Defendants Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline LLC, GlaxoSmithKline Holdings (Americas) Inc., GlaxoSmithKline ple, and Pfizer Inc. oppose the motion to vacate. In support of his motion to vacate, plaintiff argues that federal subject matter jurisdiction over Contreras is lacking and that his pending motion for remand to state court should be decided before transfer. We are not persuaded by this argument. The Panel has held that such jurisdictional objections generally do not present an impediment to transfer.! See, e.g., In re Prudential Ins. Co. of Am.…